Estrogen Receptor Modulators (Antiestrogen)

Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.

Also Known As:

Networked: 2469 relevant articles (176 outcomes, 325 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Clarke, Robert: 30 articles (05/2021 - 06/2002)
2.	Jordan, V Craig: 19 articles (05/2022 - 01/2002)
3.	Arteaga, Carlos L: 19 articles (01/2021 - 01/2003)
4.	Lykkesfeldt, Anne E: 18 articles (08/2018 - 03/2003)
5.	Miller, Todd W: 15 articles (01/2021 - 05/2009)
6.	Cook, Katherine L: 11 articles (05/2021 - 08/2011)
7.	Nephew, Kenneth P: 11 articles (01/2019 - 10/2002)
8.	Riggins, Rebecca B: 11 articles (01/2015 - 06/2004)
9.	Balko, Justin M: 10 articles (10/2017 - 04/2011)
10.	Sutherland, Robert L: 10 articles (07/2012 - 06/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/15/2010 - "These observations suggest 1 mechanism whereby AIs, which block E(2) synthesis, would be more effective for breast cancer prevention than use of antiestrogens, which only block ER-mediated effects." 01/01/2011 - "Consistent support for the hypothesis that antiestrogens are effective in reducing contralateral breast cancer risks is available from the literature. " 11/01/2005 - "These findings suggest that signal transduction inhibitors are effective for the treatment of antiestrogen-resistant breast cancer. " 08/01/2002 - "Similarly, antiestrogens have been shown to be effective both in treating breast cancer as well as preventing this disease. " 01/01/2001 - "Promising results have been achieved in breast cancer prevention with use of antiestrogens. "
2.	Neoplasms (Cancer) 06/01/2003 - "The results suggest that in ER+ tumors, FR-alpha expression is directly and actively suppressed and predict that a brief treatment with antiestrogens will boost FR-alpha expression by passive derepression, enhancing the efficacy of FR-targeted diagnostic and therapeutic applications. " 07/01/1998 - "Both antiestrogens were effective in reducing tumor growth in these mice. " 02/01/1985 - "Both antiestrogens were effective in delaying the development of secondary tumors, especially during the time of treatment. " 07/01/2003 - "Another possible explanation is that antiestrogen-liganded ER transcriptionally induces genes that are protective against cancer. " 08/01/1994 - "New antiestrogen shows promise in ER-positive breast cancers."
3.	Endometrial Neoplasms (Endometrial Cancer) 08/01/1994 - "In conclusion, pure antiestrogens may help to improve treatment of endometrial cancer." 04/01/1998 - "Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations." 01/01/1998 - "Laboratory models for breast and endometrial cancer have had an enormous impact on the clinical development of antiestrogens. " 06/01/1992 - "[Cancer of the endometrium caused by antiestrogens]." 01/01/1991 - "Overall, the ability of antiestrogens to stimulate the growth of human endometrial carcinoma EnCa101 appears to be related to their intrinsic estrogenic activity."
4.	Neoplasm Metastasis (Metastasis) 06/28/2007 - "Estimated and true 5-10 year overall survival rates from first line antiestrogen and distant metastases were higher than previously reported in a similar population. " 01/01/2023 - "Patients with lung metastasis or residual embolized AVM masses are under follow-up with antiestrogen hormonal therapy." 01/01/2003 - "The patient received antiestrogen therapy but subsequently developed skeletal metastases. " 03/01/2014 - "Our results indicate that targeting the GPR30 signaling may be a potential strategy to reduce metastasis and improve the efficacy of antiestrogens in treatment of advanced breast cancer. " 01/01/2019 - "In preclinical models of endocrine-resistant metastatic breast cancers that retain ERα expression, antiestrogens with improved efficacy and potency can overcome resistance to shrink tumors and prevent metastasis. "
5.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2004 - "However, response to antiestrogen drugs in BRCA1-blocked ER-positive ovarian cancer cells has not been reported, and this served as the rationale for this study. " 01/01/2017 - "There is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. " 01/01/2010 - "Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature." 12/01/1987 - "These results indicated that ovarian cancer containing ER, even though it originated from germ cells, would be responsible for antiestrogen therapy." 09/16/2013 - "Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase II clinical studies. "

Related Drugs and Biologics

1.	Tamoxifen
2.	Estrogen Receptors
3.	Hormones (Hormone)
4.	Aromatase Inhibitors
5.	Estrogens (Estrogen)
6.	Fulvestrant (Faslodex)
7.	Aromatase (CYP19)
8.	Toremifene (Fareston)
9.	Progesterone Receptors (Progesterone Receptor)
10.	triphenylethylene

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention
3.	Ovariectomy (Oophorectomy)
4.	Aftercare (After-Treatment)
5.	Adjuvant Chemotherapy